We have a new paper in press in "Life Sciences". This paper describes novel Chk1 inhibitors that are highly active in kinase assays and in cell-based assays. We now use Chk1 inhibitors to modify the timing of "checkpoint adaptation." The paper was a joint effort between the pharmaceutical company Servier Laboratories (France) and our own Mr Philip Kubara (his first paper).
How to see it? - go to the Pubmed website, type "golsteyn chk1" and the link will appear.
Any questions, please feel free to contact me.
